Novo Nordisk: A Duopoly, Not a WarWide moat
Eli Lilly (LLY) — moat facet
When demand grows faster than either company can manufacture, share comes from the untreated rather than from each other — that is a duopoly, not a war.
Lilly and Novo Nordisk are routinely described as locked in a battle, and the numbers describe something calmer: the two together account for roughly 87% of prescription weight-management revenue, divided about 60.1% to Lilly and 39.9% to Novo1. In the United States roughly six of every ten obesity prescriptions are for a Lilly medicine.
What makes this a duopoly rather than a war is the market's growth. When demand is expanding faster than either company can manufacture, share is won from the untreated population rather than from the other firm's patients, and neither party has any reason to compete on price. Both have spent the period constrained by capacity rather than by demand — which is the most comfortable competitive position a business can occupy.
The structure will not last indefinitely. Growth slows, capacity catches up, and at that point two suppliers with 87% of a category face the ordinary question of what to do about each other. Lilly's advantage entering that phase is efficacy data and a deeper next-generation pipeline; Novo's is a longer history with payers and a broader European position.
Watch the gap in new-to-brand prescriptions. Total share moves slowly because patients stay on what works, so the leading indicator is which company is winning the patients starting treatment this month — and that is where the oral products are currently contested.
Lilly holds roughly 60.1% against Novo's 39.9%, and about six of every ten US obesity prescriptions. In a market growing faster than either firm can manufacture, neither has reason to compete on price, and Lilly enters the eventual slowdown with better efficacy data and a deeper pipeline. The comfortable position, held and extended.
About six of every ten US obesity prescriptions are for a Lilly medicine. While demand grows faster than either company can manufacture, share comes from the untreated population and neither has reason to compete on price. Watch the new-to-brand gap, which moves years before total share does.
Source: Third-party obesity prescription data ↗- Third-party estimateThe obesity market splits ~60.1% to Lilly and ~39.9% to Novo, with ~6 of 10 US obesity prescriptions for a Lilly medicine.Third-party obesity market analysis — the prescription weight-management market splits approximately 60.1% to Eli Lilly and 39.9% to Novo Nordisk, with roughly six of every ten US obesity prescriptions written for a Lilly medicine; the two companies together control approximately 87% of prescription weight-management drug revenue — 2026 · publ. 2026 · source ↗